Literature DB >> 29189387

Ex Vivo-expanded Natural Killer Cells Derived From Long-term Cryopreserved Cord Blood are Cytotoxic Against Primary Breast Cancer Cells.

Tina Nham1, Sophie M Poznanski1, Isabella Y Fan1, Fatemeh Vahedi1, Mira M Shenouda1, Amanda J Lee1, Marianne V Chew1, Richard T Hogg1, Dean A Lee2, Ali A Ashkar1.   

Abstract

With over 600,000 units of umbilical cord blood (CB) stored on a global scale, it is important to elucidate the therapeutic abilities of this cryopreserved reservoir. In the advancing field of natural killer (NK) cell cancer immunotherapy, CB has proven to be a promising and noninvasive source of therapeutic NK cells. Although studies have proven the clinical efficacy of using long-term cryopreserved CB in the context of hematopoietic stem cell transplantations, little is known about its use for the ex vivo expansion of effector immune cells. Therefore, our group sought to derive ex vivo-expanded NK cells from long-term cryopreserved CB, using an artificial antigen presenting cell-mediated expansion technique. We compared the expansion potential and antitumor effector function of CB-derived NK (CB-NK) cells expanded from fresh (n=4), short-term cryopreserved (<1-year old, n=5), and long-term cryopreserved (1-10-year old, n=5) CB. Here, we demonstrated it is possible to obtain an exponential amount of expanded CB-NK cells from long-term cryopreserved CB. Ex vivo-expanded CB-NK cells had an increased surface expression of activating markers and showed potent antitumor function by producing robust levels of proinflammatory cytokines, interferon-γ, and tumor necrosis factor-α. Moreover, expanded CB-NK cells (n=3-5) demonstrated cytotoxicity towards primary breast cancer cells (n=2) derived from a triple-negative breast cancer and an estrogen receptor-positive/progesterone receptor-positive breast cancer patient. Long-term cryopreservation had no effect on the expansion potential or effector function of expanded CB-NK cells. Therefore, we propose that long-term cryopreserved CB remains clinically useful for the ex vivo expansion of therapeutic NK cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29189387     DOI: 10.1097/CJI.0000000000000192

Source DB:  PubMed          Journal:  J Immunother        ISSN: 1524-9557            Impact factor:   4.456


  12 in total

Review 1.  Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies.

Authors:  Florian Schütz; Frederik Marmé; Christoph Domschke; Christof Sohn; Alexandra von Au
Journal:  Breast Care (Basel)       Date:  2018-01-31       Impact factor: 2.860

2.  Inhibiting exosomal MIC-A and MIC-B shedding of cancer cells to overcome immune escape: new insight of approved drugs.

Authors:  Milad Moloudizargari; Mohammad Hossein Asghari; Esmaeil Mortaz
Journal:  Daru       Date:  2019-08-21       Impact factor: 3.117

Review 3.  Targeting myeloid-derived suppressor cells to enhance natural killer cell-based immunotherapy.

Authors:  Shweta Joshi; Andrew Sharabi
Journal:  Pharmacol Ther       Date:  2022-02-02       Impact factor: 13.400

Review 4.  Cancer Immunotherapy Based on Natural Killer Cells: Current Progress and New Opportunities.

Authors:  Weilei Hu; Guosheng Wang; Dongsheng Huang; Meihua Sui; Yibing Xu
Journal:  Front Immunol       Date:  2019-05-31       Impact factor: 7.561

5.  Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.

Authors:  Jung-Won Choi; Eui Soo Lee; Se Young Kim; Su Il Park; Sena Oh; Jung Hwa Kang; Hyun Aae Ryu; Seahyoung Lee
Journal:  BMC Cancer       Date:  2019-08-19       Impact factor: 4.430

Review 6.  Umbilical cord blood: The promise and the uncertainty.

Authors:  Tamila L Kindwall-Keller; Karen K Ballen
Journal:  Stem Cells Transl Med       Date:  2020-07-03       Impact factor: 6.940

Review 7.  Immunotherapy with NK cells: recent developments in gene modification open up new avenues.

Authors:  Lisa Marie Reindl; Nawid Albinger; Tobias Bexte; Stephan Müller; Jessica Hartmann; Evelyn Ullrich
Journal:  Oncoimmunology       Date:  2020-09-02       Impact factor: 8.110

Review 8.  Human NK cells: From development to effector functions.

Authors:  Arosh Shavinda Perera Molligoda Arachchige
Journal:  Innate Immun       Date:  2021-03-24       Impact factor: 2.680

9.  Epigenetic quantification of circulating immune cells in peripheral blood of triple-negative breast cancer patients.

Authors:  Mehdi Manoochehri; Thomas Hielscher; Nasim Borhani; Clarissa Gerhäuser; Olivia Fletcher; Anthony J Swerdlow; Yon-Dschun Ko; Hiltrud Brauch; Thomas Brüning; Ute Hamann
Journal:  Clin Epigenetics       Date:  2021-11-17       Impact factor: 6.551

Review 10.  Cord-Blood Natural Killer Cell-Based Immunotherapy for Cancer.

Authors:  Xiaoyan Zhao; Li Cai; Yu Hu; Huafang Wang
Journal:  Front Immunol       Date:  2020-10-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.